|
시장보고서
상품코드
2151502
자가 유래 줄기세포 및 비줄기세포 치료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종사용자별, 지역별 및 부문별 예측(2026-2033년)Autologous Stem Cell & Non-stem Cell Therapies Market Size, Share & Trends Analysis Report By Type, By Application, By End User, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
자가 유래 줄기세포 및 비줄기세포 치료 시장 요약
세계의 자가 유래 줄기세포 및 비줄기세포 치료 시장 규모는 2025년에 63억 달러로 평가되며, 2026년 71억 달러에서 2033년까지 175억 달러로 확대될 것으로 예상되며, 2026년부터 2033년까지 CAGR은 13.8%에 달할 것으로 예측됩니다.
북미가 시장을 주도하고 있으며, 2025년에는 매출 점유율의 41.3%를 차지했습니다. 시장의 성장은 맞춤형 치료의 확산, 만성 질환 유병률의 증가, 그리고 세포 처리, 제조 및 치료 적용 분야의 기술 발전에 의해 주도되고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 주요 요약
제3장 시장 : 변수, 동향, 범위
- 시장 계보 전망
- 시장 역학
- 업계 분석 도구
제4장 유형별 비즈니스 분석
- 자가 유래 줄기세포 및 비줄기세포 치료 시장 : 유형별 동향 분석
- 자가 유래 줄기세포
- 자가 유래 비줄기세포
제5장 용도별 비즈니스 분석
- 자가 유래 줄기세포 및 비줄기세포 치료 시장 : 용도별 동향 분석
- 암
- 신경퇴행성 질환
- 심혈관질환
- 정형외과 질환
- 기타 용도
제6장 최종사용자별 비즈니스 분석
- 자가 유래 줄기세포 및 비줄기세포 치료 시장 : 최종사용자별 동향 분석
- 병원
- 외래 수술 센터
- 연구 시설
제7장 지역별 비즈니스 분석
- 자가 유래 줄기세포 및 비줄기세포 치료 시장 점유율 : 지역별, 2025년 & 2033년
- 북미
- 북미의 자가 유래 줄기세포 및 비줄기세포 치료 시장, 2021-2033년
- 미국
- 캐나다
- 멕시코
- 유럽
- 유럽의 자가 유래 줄기세포 및 비줄기세포 치료 시장, 2021-2033년
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 아시아태평양의 자가 유래 줄기세포 및 비줄기세포 치료 시장, 2021-2033년
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
- 라틴아메리카
- 라틴아메리카의 자가 유래 줄기세포 및 비줄기세포 치료 시장, 2021-2033년
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 중동 및 아프리카의 자가 유래 줄기세포 및 비줄기세포 치료 시장, 2021-2033년
- 남아프리카공화국
- 사우디아라비아
- UAE
- 쿠웨이트
제8장 경쟁 구도
- 기업 분류
- 기업 점유율·포지셔닝 분석, 2025년
- 전략 매핑
- 기업 개요·리스트
- Kite Pharma(acquired by Gilead Sciences, Inc.)
- Bristol-Myers Squibb Company
- Novartis AG
- Janssen Pharmaceuticals, Inc.(a subsidiary of Johnson & Johnson)
- Vericel
- IOVANCE Biotherapeutics, Inc.
- JW Therapeutics(Shanghai) Co., Ltd.
- PHARMICELL Co., Ltd
- GC Cell
- ImmunoACT
- Tegoscience
- Anterogen Co., Ltd.
Autologous Stem Cell & Non-stem Cell Therapies Market Summary
The global autologous stem cell & non-stem cell therapies market size was valued at USD 6.3 billion in 2025 and is projected to grow from USD 7.1 billion in 2026 to USD 17.5 billion by 2033, at a CAGR of 13.8% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.3% in 2025. Market growth is driven by increasing adoption of personalized therapies, rising prevalence of chronic diseases, and advancements in cell processing, manufacturing, and therapeutic applications.
Global Autologous Stem Cell & Non-stem Cell Therapies Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global autologous stem cell & non-stem cell therapies market report on the basis of type, application, end user, and region.
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Autologous Stem Cells
- Autologous Non-Stem Cells
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Cancer
- Neurodegenerative Disorders
- Cardiovascular Disease
- Orthopedic Diseases
- Other Applications
- End User Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals
- Ambulatory Surgical Centers
- Research Facilities
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Type Segment
- 1.1.1.2. Application Segment
- 1.1.1.3. End User Segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information or Data Analysis:
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. List of Secondary Sources
- 1.9.3. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Growing Demand for Personalized and Patient-Specific Therapies
- 3.2.1.2. Rising Prevalence of Chronic and Degenerative Diseases
- 3.2.1.3. Increasing Clinical Research and Pipeline of Autologous Cell Therapies
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Complexity of Cell Collection, Processing, and Handling
- 3.2.2.2. Stringent Regulatory and Quality Requirements
- 3.2.3. Market Opportunities Analysis
- 3.2.4. Market Challenges Analysis
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTLE Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Economic landscape
- 3.3.2.5. Legal landscape
- 3.3.1. Porter's Five Forces Analysis
Chapter 4. Type Business Analysis
- 4.1. Segment Dashboard
- 4.2. Autologous Stem Cell & Non-stem Cell Therapies Market: Type Movement Analysis
- 4.3. Autologous Stem Cells
- 4.3.1. Autologous Stem Cells Market, 2021 - 2033 (USD Million)
- 4.4. Autologous Non-Stem Cells
- 4.4.1. Autologous Non-Stem Cells Market, 2021 - 2033 (USD Million)
Chapter 5. Application Business Analysis
- 5.1. Segment Dashboard
- 5.2. Autologous Stem Cell & Non-stem Cell Therapies Market: Application Movement Analysis
- 5.3. Cancer
- 5.3.1. Cancer Market, 2021 - 2033 (USD Million)
- 5.4. Neurodegenerative Disorders
- 5.4.1. Neurodegenerative Disorders Market, 2021 - 2033 (USD Million)
- 5.5. Cardiovascular Disease
- 5.5.1. Cardiovascular Disease Market, 2021 - 2033 (USD Million)
- 5.6. Orthopedic Diseases
- 5.6.1. Orthopedic Diseases Market, 2021 - 2033 (USD Million)
- 5.7. Other Applications
- 5.7.1. Other Applications Market, 2021 - 2033 (USD Million)
Chapter 6. End User Business Analysis
- 6.1. Segment Dashboard
- 6.2. Autologous Stem Cell & Non-stem Cell Therapies Market: End User Movement Analysis
- 6.3. Hospitals
- 6.3.1. Hospitals Market, 2021 - 2033 (USD Million)
- 6.4. Ambulatory Surgical Centers
- 6.4.1. Ambulatory Surgical Centers Market, 2021 - 2033 (USD Million)
- 6.5. Research Facilities
- 6.5.1. Research Facilities Market, 2021 - 2033 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. Autologous Stem Cell & Non-stem Cell Therapies Market Share By Region, 2025 & 2033
- 7.2. North America
- 7.2.1. North America Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Competitive Scenario
- 7.2.2.3. Regulatory Framework
- 7.2.2.4. U.S. Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Competitive Scenario
- 7.2.3.3. Regulatory Framework
- 7.2.3.4. Canada Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Competitive Scenario
- 7.2.4.3. Regulatory Framework
- 7.2.4.4. Mexico Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3.2. UK
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. UK Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. Germany Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3.4. France
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Regulatory Framework
- 7.3.4.4. France Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Competitive Scenario
- 7.3.5.3. Regulatory Framework
- 7.3.5.4. Italy Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Competitive Scenario
- 7.3.6.3. Regulatory Framework
- 7.3.6.4. Spain Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Competitive Scenario
- 7.3.7.3. Regulatory Framework
- 7.3.7.4. Denmark Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Competitive Scenario
- 7.3.8.3. Regulatory Framework
- 7.3.8.4. Sweden Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Competitive Scenario
- 7.3.9.3. Regulatory Framework
- 7.3.9.4. Norway Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Japan Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. China Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.4.4. India
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. India Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.4.5. Australia
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Competitive Scenario
- 7.4.5.3. Regulatory Framework
- 7.4.5.4. Australia Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.4.6. Thailand
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Competitive Scenario
- 7.4.6.3. Regulatory Framework
- 7.4.6.4. Thailand Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.4.7. South Korea
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Competitive Scenario
- 7.4.7.3. Regulatory Framework
- 7.4.7.4. South Korea Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Brazil Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Argentina Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.6. MEA
- 7.6.1. MEA Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. South Africa Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Saudi Arabia Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. UAE Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Kuwait Autologous Stem Cell & Non-stem Cell Therapies Market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Company Market Share/ Position Analysis, 2025
- 8.3. Strategy Mapping
- 8.4. Company Profiles/Listing
- 8.4.1. Kite Pharma (acquired by Gilead Sciences, Inc.)
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Bristol-Myers Squibb Company
- 8.4.2.1. Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Strategic Initiatives
- 8.4.3. Novartis AG
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson)
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Vericel
- 8.4.5.1. Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Strategic Initiatives
- 8.4.6. IOVANCE Biotherapeutics, Inc.
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. JW Therapeutics (Shanghai) Co., Ltd.
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. PHARMICELL Co., Ltd
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. GC Cell
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. ImmunoACT
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives
- 8.4.11. Tegoscience
- 8.4.11.1. Overview
- 8.4.11.2. Financial Performance
- 8.4.11.3. Product Benchmarking
- 8.4.11.4. Strategic Initiatives
- 8.4.12. Anterogen Co., Ltd.
- 8.4.12.1. Overview
- 8.4.12.2. Financial Performance
- 8.4.12.3. Product Benchmarking
- 8.4.12.4. Strategic Initiatives
- 8.4.1. Kite Pharma (acquired by Gilead Sciences, Inc.)
